Publications [#330238] of Michael J. Therien

Papers Published

1. Nicoll-Griffith, DA; Yergey, JA; Trimble, LA; Silva, JM; Li, C; Chauret, N; Gauthier, JY; Grimm, E; Léger, S; Roy, P; Thérien, M; Wang, Z; Prasit, P; Zamboni, R; Young, RN; Brideau, C; Chan, CC; Mancini, J; Riendeau, D, Synthesis, characterization, and activity of metabolites derived from the cyclooxygenase-2 inhibitor rofecoxib (MK-0966, Vioxx)., Bioorganic & medicinal chemistry letters, vol. 10 no. 23 (December, 2000), pp. 2683-2686 [doi]
   (last updated on 2026/01/15)

   Abstract:
   Metabolites of the COX-2 inhibitor rofecoxib (MK-0966, Vioxx) were prepared by synthetic or biosynthetic methods. Metabolites include products of oxidation, glucuronidation, reduction and hydrolytic ring opening. Based on an in vitro whole blood assay, none of the known human metabolites of rofecoxib inhibits COX-1 nor contributes significantly to the inhibition of COX-2.